Integra LifeSciences (NASDAQ:IART) Navigates Q3 2026 with Revenue Growth Amidst Price Target Adjustment

• Wells Fargo adjusted its price target for Integra LifeSciences, reflecting a new analyst outlook for the medical products stock.
• Integra LifeSciences reported a Q3 2026 revenue increase of 2.3% to $411.20 million, alongside a significant rise in diluted earnings per share to $0.19.
• The company demonstrated strong financial management, generating $96.00 million in operating cash flow and completing a $2.10 billion debt refinancing.

Integra LifeSciences (NASDAQ:IART) makes medical products used in surgery and wound care. Wells Fargo lowers its price target for the stock to $13.00 from $15.00. At the reported price of $11.84, Integra LifeSciences trades about 9.8% below the new target. A price target is an analyst’s estimate of where a stock may trade.

Integra reports third-quarter 2026 revenue of $411.20 million, up 2.3% from a year earlier. Organic revenue, which excludes the effects of acquisitions and currency changes, rises 2.5%. Flood damage at its Cincinnati facility reduces revenue by approximately $7.00 million, as highlighted by GlobeNewswire.

Earnings under standard accounting rules rise to $0.19 per diluted share from a loss of $0.07 a year earlier. Adjusted earnings, which exclude certain costs, increase to $0.59 per diluted share from $0.54. Integra generates $96.00 million in operating cash flow and lowers its total leverage ratio, a measure of debt relative to earnings, to 3.8 times.

Integra is down $1.49, or 11.18%, at $11.84. It trades between $11.57 and $13.75 during the day, compared with a past-year range of $8.70 to $20.49. Its market value is approximately $921.00 million, and about 2.02 million shares trade. After the quarter, Integra completes a $2.10 billion debt refinancing that extends repayment deadlines.